AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23648162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low VT ventilation group (VT set on 6-7 ml/kg, high pressure alarm threshold adjusted to 60 cm H2O)
Number of subjects: 40
Study 23648162 — intervention group
Group type: COMPARATOR
Intervention: Conventional VT group (VT set at 8-12 ml/kg, high pressure alarm threshold at 40 cm H2O)
Number of subjects: 40
Study 21682929 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised working memory training (25 sessions, 35 minutes each)
Number of subjects: 440
Study 21682929 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 440
Study 21682929 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised working memory training
Number of subjects: 440
Study 19107089 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School program (4 weekly classes of 60 minutes)
Number of subjects: 70
Study 19107089 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 70
Study 15005771 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut flour in mashed potatoes (2.7, 8.9, or 26.8 mg)
Number of subjects: 81
Study 15005771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnut flour in oatmeal porridge (74, 247, or 742 mg)
Number of subjects: 81
Study 15005771 — intervention group
Group type: COMPARATOR
Intervention: Placebo recipes
Number of subjects: 81
Study 10201789 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fundic wrap
Number of subjects: 24
Study 10201789 — intervention group
Group type: COMPARATOR
Intervention: Posterior partial (Toupet) fundoplication
Number of subjects: 24
Study 8642803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (RIL) 1 mg o.d. or b.i.d.
Number of subjects: 51
Study 8642803 — intervention group
Group type: COMPARATOR
Intervention: Captopril (CAP) 25 or 50 mg b.i.d.
Number of subjects: 51
Study 8642803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (RIL) and Captopril (CAP)
Number of subjects: 51
Study 2158355 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg once daily for 3 consecutive weeks
Number of subjects: 6
Study 2158355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 465434 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐complex vitamins (4 mg riboflavin and 10 mg pyridoxine) daily for 1 month
Number of subjects: 0
Study 465434 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of gentian violet
Number of subjects: 0
Study 465434 — intervention group
Group type: COMPARATOR
Intervention: No vitamin supplements
Number of subjects: 0
Study 29635953 — intervention group
Group type: EXPERIMENTAL
Intervention: Wizmi non-invasive glucose measurements
Number of subjects: 32
Study 26790204 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 279
Study 26790204 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut embedding
Number of subjects: 279
Study 26790204 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS embedding
Number of subjects: 279
Study 24810282 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational enhancement education program (25-min video, 20-min patient-centered interview, 10-min telephone follow-up)
Number of subjects: 100
Study 24810282 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational enhancement education program
Number of subjects: 100
Study 24810282 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 22743378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol (ketamine/propofol admixture)
Number of subjects: 0
Study 22743378 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 0
Study 19201317 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly filled light-cured sealant (HFLCS) - Pro Seal, Reliance Orthodontic Products, Itasca, Ill
Number of subjects: 30
Study 19201317 — intervention group
Group type: COMPARATOR
Intervention: Conventional composite resin (control group)
Number of subjects: 30
Study 17431740 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized treatment (specific intervention details not available)
Number of subjects: 31
Study 17431740 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 31
Study 15333722 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil with low phenolic content (LPC)
Number of subjects: 12
Study 15333722 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil with moderate phenolic content (MPC)
Number of subjects: 12
Study 15333722 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil with high phenolic content (HPC)
Number of subjects: 12
Study 15333722 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oils (LPC, MPC, HPC)
Number of subjects: 12
Study 11438268 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal instruction on PE skills at the beginning of the clerkship (Group A)
Number of subjects: 49
Study 11438268 — intervention group
Group type: COMPARATOR
Intervention: Instruction on PE skills at the midpoint of the clerkship (Group B)
Number of subjects: 49
Study 9736546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg loading dose on day 1, then 200 mg once daily)
Number of subjects: 419
Study 9736546 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (200 mg twice daily)
Number of subjects: 419
Study 9736546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 419
Study 9736546 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 419
Study 8293400 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 249
Study 8293400 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 249
Study 8293400 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (crossover)
Number of subjects: 249
Study 8293400 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (crossover)
Number of subjects: 249
Study 8293400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 249
Study 2620055 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 0
Study 2620055 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone pessary (3 mg)
Number of subjects: 0
Study 29513609 — intervention group
Group type: EXPERIMENTAL
Intervention: REDCap assessments
Number of subjects: 36
Study 28097941 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support (TMS)
Number of subjects: 72
Study 28097941 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 72
Study 25522347 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stigma manipulation
Number of subjects: 110
Study 24086602 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary Positive Affect (PA) persistence
Number of subjects: 540
Study 21239021 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate specific antigen screening
Number of subjects: 0
Study 19386869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with epinephrine (1:100,000)
Number of subjects: 12
Study 19386869 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 12
Study 17694489 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17694489 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra interventions
Number of subjects: 0
Study 17694489 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex interventions
Number of subjects: 0
Study 17694489 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple interventions
Number of subjects: 0
Study 15009866 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg as a 30-minute IV infusion) before electrical cardioversion
Number of subjects: 54
Study 15009866 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL IV infusion of 5% glucose) 30 minutes before electrical cardioversion
Number of subjects: 54
Study 15009866 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 54
Study 15009866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11587988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 500 microg twice daily
Number of subjects: 20
Study 11587988 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study 9861787 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for identification and resolution of medication problems
Number of subjects: 0
Study 7988630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotachysterol preparations (capsules and oral solution)
Number of subjects: 48
Study 7988630 — intervention group
Group type: COMPARATOR
Intervention: A.T.10 oral solution
Number of subjects: 48
Study 2924483 — intervention group
Group type: EXPERIMENTAL
Intervention: Plating by AO principles
Number of subjects: 59
Study 2924483 — intervention group
Group type: COMPARATOR
Intervention: External fixation with the one‐half pin technique
Number of subjects: 59
Study 29884231 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75μg every 3rd hour up to a maximum of 4 doses, then 75μg twice daily until delirium free for 2 days, discharge or a maximum of 7 days)
Number of subjects: 20
Study 29884231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28601270 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia
Number of subjects: 636
Study 28601270 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 636
Study 25865041 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin level measurement before and after TACE
Number of subjects: 42
Study 25865041 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis started 24 hours pre intervention and for 5 days after
Number of subjects: 42
Study 25865041 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory investigations including CBC, neutrophil count, C-reactive protein and ESR
Number of subjects: 42
Study 22918936 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of the nondominant upper extremity
Number of subjects: 26
Study 22918936 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 26
Study 20961566 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily nutritional supplementation for 6 months followed by daily GH therapy for 12 months
Number of subjects: 20
Study 20961566 — intervention group
Group type: COMPARATOR
Intervention: Observation for 6 months followed by daily GH therapy for 12 months
Number of subjects: 20
Study 18705808 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCP only
Number of subjects: 52
Study 18705808 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCP combined with irradiated cancellous bone
Number of subjects: 52
Study 18705808 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCP combined with intraoral autogenous bone
Number of subjects: 52
Study 16401526 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupressure with lavender oil
Number of subjects: 0
Study 16401526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16401526 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupressure group
Number of subjects: 0
Study 15319021 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 155
Study 15319021 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus psychostimulant
Number of subjects: 155
Study 15319021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 11167054 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual representation of the body
Number of subjects: 0
Study 11167054 — intervention group
Group type: COMPARATOR
Intervention: No virtual representation of the body
Number of subjects: 0
Study 9451582 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning group received a 90‐dB white noise unconditioned stimulus (UCS) paired with a frame‐lit rectangle (CS+).
Number of subjects: 20
Study 9451582 — intervention group
Group type: COMPARATOR
Intervention: Control group received non‐contingent presentations of the noise and the two rectangles (CS-).
Number of subjects: 20
Study 8103031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic intermittent impulse device
Number of subjects: 37
Study 8103031 — intervention group
Group type: COMPARATOR
Intervention: Modified impulse device (control)
Number of subjects: 37
Study 3092851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil (120 mg)
Number of subjects: 9
Study 3092851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30031369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 74
Study 30031369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cognitive Processing Therapy (SMART-CPT)
Number of subjects: 74
Study 26707905 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AMH (<1.00 ng/mL; n = 124)
Number of subjects: 1228
Study 26707905 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal AMH (1.00-3.5 ng/mL; n = 595)
Number of subjects: 1228
Study 26707905 — intervention group
Group type: EXPERIMENTAL
Intervention: High AMH (>3.5 ng/mL; n = 483)
Number of subjects: 1228
Study 26707905 — intervention group
Group type: COMPARATOR
Intervention: Low or high AMH levels compared to normal AMH
Number of subjects: 1228
Study 26707905 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG-detected pregnancy loss
Number of subjects: 1228
Study 24372829 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide nasal spray 20 mg
Number of subjects: 89
Study 24372829 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide nasal spray 10 mg
Number of subjects: 89
Study 24372829 — intervention group
Group type: COMPARATOR
Intervention: Oral metoclopramide 10 mg
Number of subjects: 89
Study 22877799 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT)
Number of subjects: 2500
Study 22877799 — intervention group
Group type: COMPARATOR
Intervention: No Defibrillation Testing (No DT)
Number of subjects: 2500
Study 20737520 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram
Number of subjects: 36
Study 20737520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18656869 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous compartment pressure monitoring
Number of subjects: 109
Study 18656869 — intervention group
Group type: COMPARATOR
Intervention: Clinical monitoring (historical control)
Number of subjects: 109
Study 15920197 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional propofol-lidocaine mixtures with 20 mg lidocaine
Number of subjects: 75
Study 15920197 — intervention group
Group type: COMPARATOR
Intervention: Propofol-MCT/LCT with saline
Number of subjects: 75
Study 15920197 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-MCT/LCT with 20 mg lidocaine
Number of subjects: 75
Study 12727037 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 134
Study 12727037 — intervention group
Group type: COMPARATOR
Intervention: Immediate release morphine sulfate (MSIR)
Number of subjects: 134
Study 10738874 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a tourniquet
Number of subjects: 65
Study 10738874 — intervention group
Group type: COMPARATOR
Intervention: Without the use of a tourniquet
Number of subjects: 65
Study 9366661 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT) program
Number of subjects: 152
Study 9366661 — intervention group
Group type: COMPARATOR
Intervention: Usual community services
Number of subjects: 152
Study 1552711 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) therapy
Number of subjects: 8
Study 1552711 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally) after baseline values
Number of subjects: 8
Study 1552711 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally) after correction of hematocrit
Number of subjects: 8
Study 1552711 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of hematocrit
Number of subjects: 8
Study 3895043 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (AS + PT)
Number of subjects: 84
Study 3895043 — intervention group
Group type: COMPARATOR
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 84
Study 30973386 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient boosting model
Number of subjects: 90785
Study 30973386 — intervention group
Group type: COMPARATOR
Intervention: CARES model
Number of subjects: 90785
Study 30973386 — intervention group
Group type: COMPARATOR
Intervention: ASA-PS model
Number of subjects: 90785
Study 29753637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg administered orally once daily (with dose reductions to 40 mg or 20 mg for adverse events)
Number of subjects: 96
Study 29753637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg administered orally once daily
Number of subjects: 96
Study 27065462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 50
Study 24237610 — intervention group
Group type: COMPARATOR
Intervention: EP42675 (1-10 mg, single ascending doses)
Number of subjects: 0
Study 24237610 — intervention group
Group type: COMPARATOR
Intervention: EP42675 (5 mg, single dose) + Aspirin (100 mg) + Clopidogrel (75 mg)
Number of subjects: 0
Study 24237610 — intervention group
Group type: COMPARATOR
Intervention: EP42675 (5 mg, second dose) + UFH (30 or 60 IU kg(‐1))
Number of subjects: 0
Study 24237610 — intervention group
Group type: EXPERIMENTAL
Intervention: EP42675 (5 mg, single dose)
Number of subjects: 0
Study 22982083 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CBT for pain and insomnia
Number of subjects: 21
Study 22982083 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT for pain
Number of subjects: 21
Study 22982083 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT for insomnia
Number of subjects: 21
Study 22982083 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 21
Study 19910928 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril, hydrochlorothiazide (HCTZ), or indapamide (INDA) for 12 weeks
Number of subjects: 94
Study 18595216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 10917
Study 18595216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10917
Study 15959362 — intervention group
Group type: EXPERIMENTAL
Intervention: X STOP interspinous process decompression system
Number of subjects: 191
Study 15959362 — intervention group
Group type: COMPARATOR
Intervention: Control (nonoperative treatment)
Number of subjects: 191
Study 12030727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 6 mg
Number of subjects: 12
Study 12030727 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 9849982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml intradermal (i.d.) PVRV
Number of subjects: 190
Study 9849982 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml intramuscular (i.m.) PVRV
Number of subjects: 190
Study 9849982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both i.d. and i.m. vaccinations
Number of subjects: 190
Study 7852216 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin (rhEPO) therapy
Number of subjects: 0
Study 7852216 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3214852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1.0 mM copper and 2.0 mM hexetidine
Number of subjects: 4
Study 3214852 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose rinse)
Number of subjects: 4
Study 31918233 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 37
Study 31918233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 29197021 — intervention group
Group type: EXPERIMENTAL
Intervention: EPVL plus ESWL
Number of subjects: 153
Study 29197021 — intervention group
Group type: COMPARATOR
Intervention: ESWL alone
Number of subjects: 153
Study 27091735 — intervention group
Group type: EXPERIMENTAL
Intervention: C-arm computed tomography (CACT)
Number of subjects: 57
Study 27091735 — intervention group
Group type: COMPARATOR
Intervention: Angiography (control)
Number of subjects: 57
Study 24917648 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMFs (pulsed electromagnetic fields) 4 hours per day for 60 days starting within 3 days after operation
Number of subjects: 30
Study 24917648 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 30
Study 23747945 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0mg fluoride tablet daily
Number of subjects: 217
Study 23747945 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 217
Study 21816067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone 12 o'clock position (PP)
Number of subjects: 150
Study 21816067 — intervention group
Group type: COMPARATOR
Intervention: Left lateral 6 o'clock position (LLP)
Number of subjects: 150
Study 19287920 — intervention group
Group type: EXPERIMENTAL
Intervention: Total face mask (TFM)
Number of subjects: 24
Study 19287920 — intervention group
Group type: COMPARATOR
Intervention: Facial mask (FM)
Number of subjects: 24
Study 19287920 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask (NM)
Number of subjects: 24
Study 19287920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure levels (low and moderate-to-high)
Number of subjects: 24
Study 16709309 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 186
Study 16709309 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg/day
Number of subjects: 186
Study 16709309 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Atorvastatin + Fenofibrate)
Number of subjects: 186
Study 16709309 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin and Combination treatment
Number of subjects: 186
Study 15540755 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 0